.4
[1]. Lauretta Maggi, et al. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing. Int J Pharm. 013 Sep 15;454(1):5-7.
[]. Lauretta Maggi, et al. II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling. Int J Pharm. 013 Sep 15;454(1):58-7.
[3]. Pratik Upadhyay, et al. Estimating relative stability of polymorphs by generation of configurational free energy phase diagram. J Pharm Sci. 01 May;101(5):1843-51.
[4]. Roberto Latini, et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Am Heart J. 013 Nov;1(5):935-40.e1.
[5]. Sajid Bashir, et al. Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method. Pak J Pharm Sci. 013 Nov;():19-35.
H30-H315-H319-H335
P1-P4-P70-P71-P80-P30+P35-P304+P340-P305+P351+P338-P330-P3+P34-P403+P33-P405-P501
![]()